Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

GLP-1 boom: no signs of slowing as sales continued to surge in 4Q24

Sales of top brands from both Lilly and Novo recorded all-time highs, again

March 5, 2025 10:41 PM UTC

The GLP-1 market continued to expand in 4Q24, with sales of the top four products, two each from Novo Nordisk and Eli Lilly, reaching new highs.

Diabetes drug Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) maintained both its lead position and upward growth trajectory. The once-weekly subcutaneous therapy has brought in over $4 billion in sales in each of the last five quarters. Its annual sales grew 25% last year, to over $17 billion. ...